HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Final MUsT Guidance For Topical OTCs Bolstered By Agency's Recent Study Results

Executive Summary

FDA final guidance on MUsTs for topically applied ingredients for OTC drug monograph affirms draft, not incorporating changes pushed by industry. CHPA says FDA’s MUsT study published recently finding sunscreen actives penetrate skin to bloodstream at higher levels than previously believed demonstrates "value" of test method.

Advertisement

Related Content

FDA MUsT Shows Sunscreen Ingredient Absorption ‘Not Just A Theoretical Concern’
'Data Gaps' Keep 12 Ingredients Off FDA's Proposed OTC Sunscreen Monograph
FDA’s MUsT Draft Guidance Extends Challenge To Wider OTC Drug Industry
Manufacturers Argue FDA Sunscreen Reviews Keep Outside Science In Shade

Topics

Advertisement
UsernamePublicRestriction

Register

RS148814

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel